Aquestive Therapeutics (AQST) Other Gross PP&E Adjustments: 2017-2025
Historic Other Gross PP&E Adjustments for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $42.6 million.
- Aquestive Therapeutics' Other Gross PP&E Adjustments rose 2.79% to $42.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.8 million, marking a year-over-year decrease of 1.30%. This contributed to the annual value of $35.3 million for FY2024, which is 0.80% up from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Other Gross PP&E Adjustments is $42.6 million, which was up 7.72% from $39.5 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Other Gross PP&E Adjustments high stood at $43.4 million for Q3 2022, and its period low was $39.0 million during Q1 2025.
- Moreover, its 3-year median value for Other Gross PP&E Adjustments was $41.2 million (2023), whereas its average is $40.9 million.
- In the last 5 years, Aquestive Therapeutics' Other Gross PP&E Adjustments declined by 7.05% in 2021 and then rose by 5.74% in 2022.
- Over the past 5 years, Aquestive Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at $41.8 million in 2021, then dropped by 3.37% to $40.4 million in 2022, then climbed by 1.78% to $41.1 million in 2023, then increased by 1.41% to $41.6 million in 2024, then grew by 2.79% to $42.6 million in 2025.
- Its last three reported values are $42.6 million in Q3 2025, $39.5 million for Q2 2025, and $39.0 million during Q1 2025.